Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated RUNX1 versus acute myeloid leukemia with myelodysplasia-related changes with mutated RUNX1. Issue 6 (11th May 2020)

• Record Type: Journal Article
• Authors: Nguyen, Lynh; Zhang, Xiaohui; Roberts, Evans; Yun, Seongseok; McGraw, Kathy; Abraham, Ivo; Song, Jinming; Braswell, Diana; Qin, Dahui; Sallman, David A.; Lancet, Jeffrey E.; List, Alan F.; Moscinski, Lynn C.; Padron, Eric; Zhang, Ling
• Is Part Of: Leukemia & lymphoma. Volume 61:Issue 6(2020)
• Page Start: 1395
• Page End: 1405
• Publication Date: 2020-05-11
• Subjects: RUNX1 -- AML -- AML-MRC -- NGS; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2020.1723016
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Studies comparing the prognostic role of RUNX1 mutations ( RUNX1 mut ) in acute myeloid leukemia (AML) and acute myeloid leukemia-with myelodysplasia-related changes (AML-MRC) are limited. Our study examines the genetic profile of 118 RUNX1 mut AML patients including 57 AML with RUNX1 mut and 61 AML-MRC with RUNX1 mut and 100 AML, NOS patients with wild type RUNX1 ( RUNX1 wt ). Results revealed that AML-MRC patients with RUNX1 mut had shorter median overall survival (OS) (11 ± 3.3 months) when compared to AML with RUNX1 mut (19 ± 7.1 months) and AML, NOS with RUNX1 wt (not reached) ( p = .001). The most common concurrent mutations observed in AML-MRC with RUNX1 mut patients were DNMT3A, SRSF2, ASXL1, and IDH2 while in AML with RUNX1 mut patients were ASXL1, SRSF2, TET2, IDH2, and DNMT3A . ASXL1 and TET2 mutations appeared to adversely affect OS in AML-MRC, but not in AML with RUNX1 mut . Concurrent RUNX1/DNMT3A mutations, in contrast had negative impact on OS in AML with RUNX1 mut, but not in AML-MRC with RUNX1 mut .